Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds

Regeneron Pharmaceutical Inc.’s REGN COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found.

What Happened: Regeneron said that the Phase 3 RECOVERY trial met the primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to the coronavirus.

The UK RECOVERY trial is the first trial large enough to definitively determine whether the therapy, REGEN-COV, reduces mortality in patients hospitalized with severe COVID-19.

The trial showed that adding the antibody therapy to usual care reduced the mortality by a fifth the 28-day mortality of COVID-19 patients whose immune system had not mounted a natural antibody response of their own, known as seronegative.

Why It Matters: REGEN-COV has not been approved by the U.S. Food and Drug Administration (FDA), but is currently granted Emergency Use Authorization (EUA) for people with mild-to-moderate COVID-19 in the U.S.

Regeneron said it will request that the EUA be expanded to include appropriate hospitalized patients.

Price Action: Regeneron Pharma shares closed 0.2% lower in Tuesday’s trading at $527.49.

 

Posted In: AntibodiesCovid-19BiotechNewsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.